[News Space=Reporter seungwon lee] Osstem Pharma (CEO Moon Byeong-jeom), a subsidiary of Osstem Implant, announced that it received enthusiastic interest and response by introducing an exhibition booth for its premium oral care brand 'Viewsen' at the 'China Beauty Expo 2025 (CBE)' held at the Shanghai International Expo Center from May 12 to 14. CBE is the largest beauty trade show in Asia. This year, in its 29th year, over 3,500 companies from 80 countries around the world opened booths and attracted over 500,000 visitors. Osstem Pharma set up a brand promotion booth centered around the Views
[News Space=Reporter seungwon lee] Despite the increase in sales in 2024, Novartis Korea (CEO Yoo Byung-jae) saw its profitability decline as both operating profit and net profit decreased. The operating profit ratio also fell to 3.7%. In addition, short-term borrowings increased and cash assets remain at 0 won, making liquidity management weak. The scale of purchases and debts with special related parties (head office, etc.) is large, and the financial structure has improved somewhat due to inventory asset reduction and restructuring (dramatic reduction in retirement benefits), but the group
[News Space=Reporter seungwon lee] Celltrion has successfully expanded its coverage by signing a formulary listing contract for its autoimmune disease treatment drug 'Steqeyma' (ingredient name: ustekinumab) with one of the top five prescription drug benefit managers (PBM) in the United States. As Celltrion secures the private insurance area under the jurisdiction of the PBM through this contract, Stekima is scheduled to receive a refund starting July 1. This contract is the second achievement that Celltrion has made with a large US PBM for the listing of Stekima in the formulary. Prior to thi
[News Space=Reporter seungwon lee] Daewon Pharmaceutical, once the pride of domestic new drugs, has lost four consecutive patent lawsuits for ‘Pelubi’ from the first trial to the Supreme Court, exposing its management incompetence and structural risks at once. In recent years, Daewon Pharmaceutical has been criticized as a typical ‘bad company’ due to repeated investigations by the Ministry of Food and Drug Safety and the National Tax Service, as well as repeated defeats in court. ◆ Four consecutive patent lawsuit losses… The fall of the Pelubi myth Daewon Pharmaceutical’s domestic new drug ‘P
[News Space=Reporter seungwon lee] The symbol of Korean manufacturing: Hyundai and Kia Motors factories. The workers there are called “new production workers” with hundreds of millions of won in annual salaries, but behind the splendid facade, there are industrial accidents, occupational diseases, and the tears of subcontracted workers. Even more shocking is the tyranny of Hyundai and Kia Motors, which evades all responsibility with their powerful power and capital. Over the past five years, more than 2,061 people were injured, and 28 people lost their lives… “Passing responsibility to subcont
[News Space=Reporter seungwon lee] Another worker death accident has occurred at Hyundai Motor Company and Kia Motors plants. Following the accident at Kia's Gwangju plant on May 16 in which a worker in his 40s was caught in a machine transporting a finished vehicle and died, the two companies' plants have been experiencing a series of serious accidents in recent years, including entrapment, falls, and suffocation. Although it is a job that boasts an annual salary in the hundreds of millions, to the point that it is called a 'new production job,' it is pointed out that backward and repetitive
[News Space=Reporter seungwon lee] As Daewon Pharmaceutical lost the patent lawsuit for its representative domestic new drug 'Pelubi' in the first and second trials, as well as in the third trial at the Supreme Court, the lack of strategy and crisis management capabilities of the management were clearly revealed. As this ruling makes it virtually inevitable for the drug price of Peluvi to be lowered, a sales decrease of hundreds of billions of won is expected to become a reality. ◆ Another lawsuit after losing four times?… Key reason for losing four times in a row Daewon Pharmaceutical has los
[News Space=Reporter seungwon lee] ABC Mart Korea (CEO Lee Ki-ho, hereinafter referred to as ABC Mart), the No. 1 domestic shoe distributor, exceeded KRW 600 billion in sales in 2023 and continued its growth in 2024, but its operating profit and net profit decreased slightly. Major risks include the structure of profit outflows such as royalties and dividends to the Japanese headquarters, the burden of selling and administrative expenses, sluggish performance at some stores, and uncertainty in overseas new businesses. On the other hand, financial stability, including debt ratio and liquidity,
The sigh of an engineer visiting a construction site in Gurae-dong, Gimpo City, captures the reality of South Korea’s data center industry: “It’s been three years since groundbreaking, but we’re still only working on the foundation.” While artificial intelligence and cloud computing continue to advance at a rapid pace, the data centers that underpin these technologies remain stalled. Growing Demand, Stalled Construction Between 2025 and 2029, a total of 732 data centers are scheduled for development across South Korea, with 56% concentrated in Gyeonggi Province. Within the Seoul metropolitan a
Director Ryu is a seasoned expert with over 15 years of experience dedicated exclusively to the research field. During his tenure at IGIS Asset Management, he developed the IGIS-Daishin Seoul Office Transaction Price Index. He has also built a strong academic track record, having published 32 papers over the course of his career. He joined RSQUARE in June 2022. Director Ryu explained, “We have 60 to 70 staff members dedicated exclusively to research—a significant difference compared to most competitors, who typically operate with research teams in the single digits.” He added, “This depth of s
서울시 서초구 사평대로 140 코웰빌딩 B1, 318호 | 대표전화 : 0505-546-0505 | 팩스 : 0505-548-0505
제호 : 뉴스스페이스(NewsSpace) | 등록번호 : 서울 아 54727 | 등록일 : 2023-03-07 | 발행일 : 2023-03-07 | 발행·편집인 : 이현주 | 청소년보호책임자 : 김정영
Copyright © 2024 뉴스스페이스(NewsSpace). All rights reserved.
UPDATE: 2025년 09월 02일 21시 59분
